Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Marta MaschioAlessia ZarablaAndrea MaialettiFrancesco MarchesiDiana GiannarelliSvitlana GumenyukFrancesco PisaniDaniela RenziEdvina GalièAndrea MengarelliPublished in: Integrative cancer therapies (2018)
Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial.
Keyphrases
- neuropathic pain
- multiple myeloma
- spinal cord
- spinal cord injury
- electronic health record
- big data
- clinical trial
- physical activity
- newly diagnosed
- current status
- cerebral ischemia
- data analysis
- stem cells
- artificial intelligence
- human health
- subarachnoid hemorrhage
- mesenchymal stem cells
- cell therapy
- smoking cessation